Drug Profile
ABL 002
Alternative Names: ABL002Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator ABL Bio
- Class Antineoplastics; Bispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Head and neck cancer
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Head-and-neck-cancer in South Korea (Parenteral)
- 28 Nov 2018 WuXi Biologics and ABL Bio enters into an exclusive development and clinical manufacturing partnership for multiple bispecific antibodies
- 09 Mar 2017 Early research in Head and neck cancer in South Korea (Parenteral)